All In Biotech

Drug Trial Radar · NCT07030517

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate Its Safety in Indian Participants With Relapsed and Refractory Multiple Myeloma Who Have Previously Received at Least 3 Prior Lines of Therapy Including an Immunomodulatory Agent, a Proteasome Inhibitor and an Anti-CD38 Antibody and Have Demonstrated Disease Progression on the Last Therapy

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Actual

Start

May 22, 2025

Primary completion

Feb 12, 2027

Study completion Feb 14, 2027

Sponsor

Lead sponsor
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.

Conditions

  • Multiple Myeloma

Interventions

  • TeclistamabDrug

    Teclistamab will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAE)sTime frame: Up to approximately 2 years 1 month

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • M S Ramaiah Medical College and Hospital

    Bangalore, India

  • St. Johns Medical College And Hospital

    Bengaluru, India

  • Post Graduate Institute of Medical Education And Research PGIMER

    Chandigarh, India

  • Bhagwan Mahaveer Cancer Hospital & Research Centre

    Jaipur, India

  • Tata Medical Center

    Kolkata, India

  • Tata Memorial Hospital

    Mumbai, India

  • KIMS-Kingsway Hospitals

    Nagpur, India

  • All India Institute of Medical Sciences

    New Delhi, India

  • Rajiv Gandhi Cancer Institute & Research Centre

    New Delhi, India

  • Jawaharlal Institute of Postgraduate Medical Education and Research

    Puducherry, India

  • Christian Medical College

    Ratnagiri Kilminnal, India

  • Regional Cancer Centre

    Thiruvananthapuram, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.